Trial Profile
A phase II randomised trial of biomarkers to assess (dose-) response in patients with metastatic castration resistant prostate cancer treated with radium-223
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Oct 2023
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Biomarker; Therapeutic Use
- Acronyms REASURE
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2018 Results (n=27) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 22 Jun 2017 Status changed from recruiting to active, no longer recruiting.